StreetAlpha.app
Home › Stocks › TGTX

TG Therapeutics, Inc. (TGTX)

Healthcare
$62.71
▼ −0.08%
LAST CLOSE · NOV 17

TG Therapeutics develops and sells BRIUMVI, a treatment for multiple sclerosis, to physicians and patients. It last closed at $62.71 on Nov 17, down 0.08% on the day. The average 12-month price target from 2 analysts is $74.50 (+18.8% from the last close), with a high of $78.00 and a low of $71.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in TGTX, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $1.5M, the largest $941K.

AI Auto Pilots
Is TGTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$897.8M
+68.8% vs a year ago
Net income
$106.1M
−76.3% vs a year ago
EPS (diluted)
$0.67
−75.8% vs a year ago
Free cash flow
$85.6M
9.5% margin
Valuation
Market cap
$9.5B
151.1M shares
P/E
93.6
Price over 12 month EPS
Price to sales
10.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$429.4M
At Sep 30
Debt
$745.6M
At Sep 30
Shareholder equity
$572.1M
Shares outstanding
151.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $6.7M$6.7MFY2021FY2022: $2.8M$2.8MFY2022FY2023: $233.7M$233.7MFY2023FY2024: $329.0M$329.0MFY2024FY2025: $616.3M$616.3MFY2025

From TGTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated TGTX in the past 90 days, not enough for a consensus
Average 12-month target
$74.50
▲ 18.8% upside

Based on 2 analysts who set a price target on TGTX in the past 90 days. The average target is $74.50, with a high of $78.00 and a low of $71.00, compared with the last close of $62.71.

Low $71.00Avg $74.50High $78.00
Blue marker: last close $62.71
Highest target$78.00
Average target$74.50
Lowest target$71.00
Latest rating changes
Evercore ISI GroupMaintained
Nov 10Buy$71
HC Wainwright & Co.Target raised
Sep 1Buy$77 → $78
JP MorganMaintained
Aug 7Buy$72
B. Riley SecuritiesMaintained
Jul 27Buy$86
HC Wainwright & Co.Target raised
Jul 13Buy$70 → $77
DateFirmActionRatingPrice target
Nov 10Evercore ISI GroupMaintainedBuy$71
Sep 1HC Wainwright & Co.Target raisedBuy$77 → $78
Aug 7JP MorganMaintainedBuy$72
Jul 27B. Riley SecuritiesMaintainedBuy$86
Jul 13HC Wainwright & Co.Target raisedBuy$70 → $77
Loading…

Technical Analysis

TGTX · as of the Nov 17 close · updated after every close
Uptrend

The stock is 5% above its 20 day and 9% above its 50 day average. It is 27% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 59). The nearest support is the Pivot at $62.59, and the nearest resistance the swing high (Nov 2) at $63.58.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 4.8%/day
Key levels
$68.0352 week high+8.5%
$63.69Pivot R1+1.6%
$63.58Swing high (Nov 2)+1.4%
$62.71Last close
$62.59Pivot−0.2%
$61.62Pivot S1−1.7%
$59.8320 day average−4.6%
$56.9750 day average−9.2%
$55.28100 day average−11.8%
$54.78Swing low (Sep 23)−12.6%
$45.71200 day average−27.1%
$26.7652 week low−57.3%
Indicators
RSI (14)59.20Middle of its rangeNeutral
MACD2.29Above its signal lineBullish
Stochastic65.4Middle of its rangeNeutral
ADX (14)22.4Weak trend
Williams %R-39.6Oversold below −80, overbought above −20Neutral
CCI (20)59.9Oversold below −100, overbought above 100Neutral
Rate of change+3.2%Change over 10 sessionsBullish
ATR (14)$3.02Typical daily range, 4.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for TGTX

What happened before

See how TGTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TGTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TGTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Nov 11 – Nov 11
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.5M
Largest print
$941K
Loading…

TGTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲243 buying vs 183 selling
  • ▲Held by funds +3.5 pts
  • ▲Funds holding +24
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding455431+5.6%
In funds' top 1097+28.6%
Held by funds77.1%73.6%+3.5 pts
New / increased76 / 167101 / 149−2.8%
Reduced / sold out136 / 47122 / 36+15.8%
Put/call ratio0.260.61−57.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TGTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TGTX is in one of them and how their past TGTX trades turned out.

TGTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TGTX in an article yet. Here's the latest on the wider market.

TGTX Congress Trades

All congress trades →
Trades, 12 months
5
Buys
2
40%
Sells
3
60%
People
1
Last filed Sep 22
Who traded TGTX · since 2020
Latest 5 filings of 6
$1K – $15KTraded Jul 29, 2026Filed Sep 22, 2026
$1K – $15KTraded May 15, 2026Filed Jul 1, 2026
$15K – $50KTraded Jan 26, 2026Filed May 14, 2026
$15K – $50KTraded Mar 4, 2025Filed May 14, 2026
$50K – $100KTraded Feb 26, 2025Filed May 14, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$1K – $15KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$1K – $15KMay 15, 2026Jul 1, 202647 d
Donald J TrumpExecutive branchSell$15K – $50KJan 26, 2026May 14, 2026108 d
Donald J TrumpExecutive branchBuy$15K – $50KMar 4, 2025May 14, 2026436 d
Donald J TrumpExecutive branchBuy$50K – $100KFeb 26, 2025May 14, 2026442 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About TG Therapeutics

TG Therapeutics is a biotechnology company that develops and sells treatments for diseases driven by B cells, with its main focus on multiple sclerosis. Its approved product, BRIUMVI, is a monoclonal antibody given as an infusion lasting about an hour every 24 weeks to adults with relapsing forms of multiple sclerosis. Its customers include physicians and patients in the United States, and a commercial partner sells the treatment in several other countries. The company is based in Morrisville, North Carolina.

Headquarters
New York, NY